Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to BENLYSTAŽ (belimumab) as a potential treatment for systemic lupus erythematosus (SLE)...

More...